(PEG) Pharma Equity Group Cl A - Ratings and Ratios
Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0061155009
PEG: Bacterial, Skin, Inflammatory, Bowel, Cancer, Ulcer treatments
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark. Web URL: https://www.pharmaequitygroup.com
Additional Sources for PEG Stock
PEG Stock Overview
| Market Cap in USD | 30m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Coal & Consumable Fuels |
| IPO / Inception |
PEG Stock Ratings
| Growth 5y | -95.8% |
| Fundamental | -38.6% |
| Dividend | - |
| Rel. Strength Industry | -59.5 |
| Analysts | - |
| Fair Price Momentum | 0.09 DKK |
| Fair Price DCF | - |
PEG Dividends
No Dividends PaidPEG Growth Ratios
| Growth Correlation 3m | 21.1% |
| Growth Correlation 12m | -86.2% |
| Growth Correlation 5y | -89.3% |
| CAGR 5y | -39.66% |
| CAGR/Mean DD 5y | -0.59 |
| Sharpe Ratio 12m | -0.87 |
| Alpha | -64.63 |
| Beta | 0.25 |
| Volatility | 82.81% |
| Current Volume | 186.7k |
| Average Volume 20d | 633.6k |
What is the price of PEG stocks?
As of January 30, 2025, the stock is trading at DKK 0.16 with a total of 186,685 shares traded.
Over the past week, the price has changed by -5.83%, over one month by -15.00%, over three months by -17.18% and over the past year by -55.39%.
As of January 30, 2025, the stock is trading at DKK 0.16 with a total of 186,685 shares traded.
Over the past week, the price has changed by -5.83%, over one month by -15.00%, over three months by -17.18% and over the past year by -55.39%.
Is Pharma Equity Group Cl A a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Pharma Equity Group Cl A (CO:PEG) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -38.62 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PEG as of January 2025 is 0.09. This means that PEG is currently overvalued and has a potential downside of -43.75%.
Probably not. Based on ValueRay Fundamental Analyses, Pharma Equity Group Cl A (CO:PEG) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -38.62 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PEG as of January 2025 is 0.09. This means that PEG is currently overvalued and has a potential downside of -43.75%.
Is PEG a buy, sell or hold?
Pharma Equity Group Cl A has no consensus analysts rating.
Pharma Equity Group Cl A has no consensus analysts rating.
What are the forecast for PEG stock price target?
According to ValueRays Forecast Model, PEG Pharma Equity Group Cl A will be worth about 0.1 in January 2026. The stock is currently trading at 0.16. This means that the stock has a potential downside of -37.5%.
According to ValueRays Forecast Model, PEG Pharma Equity Group Cl A will be worth about 0.1 in January 2026. The stock is currently trading at 0.16. This means that the stock has a potential downside of -37.5%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.1 | -37.5% |